WO2003037888A1 - 3-substituted-4-pyrimidone derivatives - Google Patents
3-substituted-4-pyrimidone derivatives Download PDFInfo
- Publication number
- WO2003037888A1 WO2003037888A1 PCT/JP2002/009685 JP0209685W WO03037888A1 WO 2003037888 A1 WO2003037888 A1 WO 2003037888A1 JP 0209685 W JP0209685 W JP 0209685W WO 03037888 A1 WO03037888 A1 WO 03037888A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methyl
- pyridin
- pyrimidin
- morpholin
- Prior art date
Links
- 0 CN(CC*1)CC1C(*)=O Chemical compound CN(CC*1)CC1C(*)=O 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases mainly caused by abnormal activity of tau protein kinase 1, such as neurodegenerative diseases (e.g. Alzheimer disease).
- diseases mainly caused by abnormal activity of tau protein kinase 1 such as neurodegenerative diseases (e.g. Alzheimer disease).
- Alzheimer disease is progressive senile dementia, in which marked cerebral cortical atrophy is observed due to degeneration of nerve cells and decrease of nerve cell number.
- Pathologically numerous senile plaques and neurofibrillary tangles are observed in brain. The number of patients has been increased with the increment of aged population, and the disease arises a serious social problem.
- various theories have been proposed, a cause of the disease has not yet been elucidated. Early resolution of the cause has been desired.
- THF paired helical filament
- presenilins 1 and 2 were found as causative genes of familial Alzheimer disease (Nature, 375, 754 (1995); Science, 269, 973 (1995); Nature. 376, 775 (1995)), and it has been revealed that presence of mutants of presenilins 1 and 2 promotes the secretion of A j3 (Neuron, 17, 1005 (1996); Proc. Natl. Acad. Sci. USA, 94, 2025 (1997)). From these results, it is considered that, in Alzheimer disease, A ⁇ abnormally accumulates and agglomerates due to a certain reason, which engages with the formation of PHF to cause death of nerve cells.
- a ⁇ diseases in which abnormal accumulation and agglomeration of A ⁇ are observed include, for example, Down syndrome, cerebral bleeding due to solitary cerebral amyloid angiopathy, Lewy body disease (Shin-kei Shinpo [Nerve Advance], 34, 343 (1990); Tanpaku-shitu Kaku-san Koso [Protein, Nucleic Acid, Enzyme], 41, 1476 (1996)) and the like.
- examples include progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease and the like (Tanpakushitu Kakusan Koso [Protein, Nucleic Acid, Enzyme], 36, 2 (1991); Igaku no Ayumi [Progress of Medicine], 158, 511 (1991); Tanpakushitu Kakusan Koso [Protein, Nucleic Acid, Enzyme], 41, 1476 (1996)).
- the tau protein is generally composed of a group of related proteins that forms several bands at molecular weights of 48-65 kDa in SDS-polyacrylamide gel electrophoresis, and it promotes the formation of microtubules. It has been verified that tau protein incorporated in the PHF in the brain suffering from Alzheimer disease is abnormally phosphorylated compared with usual tau protein (J. Biochem., 99, 1807 (1986); Proc. Natl. Acad. Sci. USA, 83, 4913 (1986)). An enzyme catalyzing the abnormal phosphorylation has been isolated.
- TPK1 tau protein kinase 1
- cDNA of rat TPK1 was cloned from a rat cerebral cortex cDNA library based on a partial amino acid sequence of TPK1, and its nucleotide sequence was determined and an amino acid sequence was deduced (Japanese Patent Un-examined Publication [Kokai] No. 6-239893/1994).
- rat TPK1 corresponds to that of the enzyme known as rat GSK-3 ⁇ (glycogen synthase kinase 3 ⁇ , FEBS Lett., 325, 167 (1993)).
- compounds which inhibit the TPKl activity may possibly suppress the neurotoxicity of A and the formation of PHF and inhibit the nerve cell death in the Alzheimer disease, thereby cease or defer the progress of the disease.
- the compounds may also be possibly used as a medicament for therapeutic treatment of ischemic cerebrovascular disorder, Down syndrome, cerebral amyloid angiopathy, cerebral bleeding due to Lewy body disease and the like by suppressing the cytotoxicity of A ⁇ .
- the compounds may possibly be used as a medicament for therapeutic treatment of neurodegenerative diseases such as progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma, as well as other diseases such as non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and several virus-induced tumors.
- neurodegenerative diseases such as progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkins
- R represents 2,6-dichlorobenzyl group, 2-(2-chlorophenyl)ethylamino group, 3-phenylpropylamino group, or l-methyl-3-phenylpropylamino group (W098/24782).
- the compounds represented by formula (A) are characterized to have 4-fluorophenyl group at the 5-position of the pyrimidine ring and a hydroxy group at the 4-position, and not falling within the scope of the present invention.
- main pharmacological activity of the compounds represented by formula (A) is anti-inflammatory effect
- the compounds of the present invention represented by formula (I) are useful as a TPKl inhibitor or a medicament for therapeutic treatment of neutodegenerative diseases, and therefore, their pharmacological activities are totally different to each other.
- An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases such as Alzheimer disease. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables radical prevention and/or treatment of the neurodegenerative diseases such as Alzheimer disease by inhibiting the TPKl activity to suppress the neurotoxicity of A ⁇ and the formation of the PHF and by inhibiting the death of nerve cells.
- the present invention thus provide a pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof:
- R 1 represents a C1-C12 alkyl group which may be substituted
- R represents any one of groups represented by the following formulas (II) to (V):
- R 2 and R 3 independently represent a hydrogen atom or a Ci-Cs alkyl group
- R 4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total;
- R 5 represents a Ci-Cs alkyl group which may be substituted, a C3-C8 cycloalkyl group which may be substituted, a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total;
- R 6 represents a hydrogen atom, a Ci-Cs alkyl group which may be substituted, a benzene ring which may be substituted; or R 5 and R 6 may bind to each other to form together with the carbon to which R 5 and
- R 6 are attached an optionally substituted spiro carbocyclic ring having 3 to 11 ring-constituting atoms in total;
- R 7 and R 8 independently represent a hydrogen atom or a Ci-Cs alkyl group, or R 7 and
- R 8 may combine to each other to form a C2-C6 alkylene group
- R 9 and R 10 represent a Ci-Cs alkyl group which may be substituted, a C3-C8 cycloalkyl group which may be substituted, a benzene ring which may be substituted, a naphthalene ring which may be substituted, an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total, or R 9 and R 10 represent -N(R n )(R 12 ) wherein R u represents a hydrogen atom, a Ci-Cs alkyl group; and R 12 represents a Ci-Cs alkyl group, a benzene ring which may be substituted, a naphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen
- the present invention provides a medicament comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivative represented by the aforementioned formula (I) and a salt thereof, and a solvate thereof and a hydrate thereof, and a tau protein kinase 1 inhibitor selected from the group consisting of the pyrimidone derivative represented by the aforementioned formula (I) and a salt thereof, and a solvate thereof and a hydrate thereof.
- the aforementioned medicament which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity; the aforementioned medicament which is used for preventive and/or therapeutic treatment of a neurodegenerative disease; the aforementioned medicament, wherein the disease is selected from the group consisting of Alzheimer disease, ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma; and the aforementioned medicament, wherein the disease is selected from the group consisting of non-insulin
- a method for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity comprises the step of administering to a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of the 3-substituted-4-pyrimidone derivative of formula (I) and the physiologically acceptable salt thereof, and the solvate thereof and the hydrate thereof; and a use of a substance selected from the group consisting of the 3-substituted-4-pyrimidone derivative of formula (I) and the physiologically acceptable salt thereof, and the solvate thereof and the hydrate thereof for the manufacture of the aforementioned medicament.
- pyrimidone derivative represented by formula (VI) or a salt thereof, or a solvate thereof or a hydrate thereof:
- R 1 represents a C1-C12 alkyl group which may be substituted, and a pyrimidone derivative represented by formula (VII) or a salt thereof, or a solvate thereof or a hydrate thereof:
- R 1 represents a C1-C12 alkyl group which may be substituted.
- the alkyl group used herein may be either linear or branched.
- the C1-C12 alkyl group represented by R 1 may be, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, n-hexyl group, isohexyl group, or a linear or branched heptyl group, octyl group, nonyl group, decyl group, undecyl group or dodecyl group.
- the alkyl group may have one or more substituents selected from the group consisting of a C1-C5 alkoxyl group such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, tert-butoxy group; amino group, C1-C3 alkylamino group or C2-C6 dialkylamino group: a C ⁇ -Cio aryl group such as phenyl group, 1-naphthyl group, and 2-naphthyl group;
- the Ci-Cs alkyl group represented by R 2 or R 3 may be, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, n-hexyl group, isohexyl group, or a linear or branched heptyl group or octyl group.
- the rings may have one or more substituents selected from the groups consisting of a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; C3-C6 cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C3-C6 cycloalkyloxy group such as cyclopropyloxy group, cyclobutyloxy
- the substituent may further have one or more substituents selected from the group consisting of a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; C3-C6 cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C3-C6 cycloalkyloxy group such as cyclopropyloxy group, cyclobutyloxy group, cyclopent
- a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-
- the heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms represented by R 4 or R 5 may be, for example, furan ring, dihydrofuran ring, tetrahydrofuran ring, pyran ring, dihydropyran ring, tetrahydropyran ring, benzofuran ring, dihydrobenzofuran, isobenzofuran ring, benzodioxole ring, chromene ring, chroman ring, isochroman ring, thiophene ring, benzothiophene ring, pyrrole ring, pyrroline ring, pyrrolidine ring, imidazole ring, imidazoline ring, imidazolidine ring, pyrazole ring, pyrazoline ring, pyrazolidine ring, triazole ring,
- the Ci-C ⁇ alkyl group represented by R 5 , R 6 , R 7 or R 8 may be, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, n-hexyl group, isohexyl group, or a linear or branched heptyl group or octyl group.
- the C3-C8 cycloalkyl group represented by R 5 may be, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group or cyclooctyl group.
- the group may have one or more substituents selected from the groups consisting of a halogen atom, a Ci-C ⁇ alkoxyl group, a C ⁇ -C ⁇ cycloalkyl group, a benzene ring which may be substituted, a naphthalene ring which may be substituted, phenoxy group which may be substituted or phenylamino group which may be substituted; amino group, a Ci-C ⁇ alkylamino group, a C2-C12 dialkylamino group, 1-pyrrolidinyl group, 1-pyperidinyl group, 1-morpholinyl group, l-(tetrahydro-l,2,3,4-quinolinyl) group, or l-(tetrahydro- 1,2,3,4-isoquinolinyl
- the ring may have one or more substituents selected from the group consisting of a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; a C ⁇ -C ⁇ cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C3-C6 cycloalkyloxy group such as cyclopropyloxy group, cyclobutyloxy group, cyclopentyloxy group, cyclohexyloxy group; a C1-C5 alkoxyl group such as methoxy
- the substituent may further have one or more substituents selected from the groups consisting of a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; C3-C6 cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C3-C6 cycloalkyloxy group such as cyclopropyloxy group, cyclobutyloxy group, cyclopentyloxy group, cyclohexyloxy group; a C1-C5 alkoxyl group such as methoxy group
- the carbocyclic ring may be, for example, cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, cyclohexyl ring, cycloheptyl ring, tetrahydrobenzocycloheptene ring, tetrahydronaphthalene ring, indane ring, bicyclo[4,2,0]octa-l,3,5-triene ring.
- the Ci-C ⁇ alkyl group represented by R 9 , R 1 ", R 11 , R 12 or R* 3 may be, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, n-hexyl group, isohexyl group, or a linear or branched heptyl group or octyl group.
- the C3-C8 cycloalkyl group represented by R 9 or R 10 may be, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group or cyclooctyl group.
- the group may have one or more substituents selected from, for example, the groups consisting of a halogen atom, C3-C8 cycloalkyl group, a benzene ring which may be substituted, a naphthalene ring which may be substituted, an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.
- substituents selected from, for example, the groups consisting of a halogen atom, C3-C8 cycloalkyl group, a benzene ring which may be substituted, a naphthalene ring which may be substituted, an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.
- the ring may have one or more substituents selected form the group consisting of a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; C ⁇ -C ⁇ cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C3-C6 cycloalkyloxy group such as cyclopropyloxy group, cyclobutyloxy group, cyclopentyloxy group, cyclohexyloxy group
- the heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total represented by R 9 or R 10 may be, for example, furan ring, dihydrofuran ring, tetrahydrofuran ring, pyran ring, dihydropyran ring, tetrahydropyran ring, benzofuran ring, dihydrobenzofuran, isobenzofuran ring, benzodioxol ring, chromene ring, chroman ring, isochroman ring, thiophene ring, benzothiophene ring, pyrrole ring, pyrroline ring, pyrrolidine ring, imidazole ring, imidazoline ring, imidazolidine ring, pyrazole ring, pyrazoline ring, pyrazolidine ring, triazole
- the ring may be substituted by one or more substituents selected from the groups consisting of halogen atoms, a C1-C5 alkyl group, a C3-C6 cycloalkyl group, a C3-C6 cycloalkyloxy group, a C1-C5 alkoxy group, a C4-C7 cycloalkylalkoxy, a C1-C5 alkylthio group, a C1-C5 alkylsulfonyl group, a C1-C5 halogenated alkyl, and a benzene ring.
- substituents selected from the groups consisting of halogen atoms, a C1-C5 alkyl group, a C3-C6 cycloalkyl group, a C3-C6 cycloalkyloxy group, a C1-C5 alkoxy group, a C4-C7 cycloalkylalkoxy, a C1-C
- the substituent may further have one or more substituents selected from the group consisting of a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; C3-C6 cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C3-C6 cycloalkyloxy group such as cyclopropyloxy group, cyclobutyloxy group, cyclopentyloxy group, cyclohexyloxy group; a C1-C5 alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, but
- R 1 may preferably be a C1-C3 alkyl group, more preferably a methyl group.
- R 2 may preferably be a hydrogen atom.
- R 3 may preferably be a hydrogen atom.
- R 4 may preferably be a benzene ring which may be substituted.
- R 5 may preferably be a benzene ring or a naphthalene ring which may be substituted.
- R 6 may preferably be a hydrogen atom.
- R 7 and R 8 may preferably be a hydrogen atom or a C1-C3 alkyl group.
- R 9 or R 10 may preferably be a benzene ring which may be substituted.
- R 10 may preferably be a heterocyclic ring having 1-4 hetero atoms selected oxygen atom, sulfur atom and nitrogen atom, and having total ring-constituting atoms of 5-10 which may be substituted.
- Particularly preferred R 10 is a benzene ring which may be substituted, a 2,3-dihydroindole ring which may be substituted, or 3,4-dihydro-2H-quinoline ring which may be substituted.
- Particularly preferred X is CH2 or O.
- the compounds represented by the aforementioned formula (I) may form a salt.
- the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, 2-amino-2-methyl-l-propanol, ethanolamine, N-methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, ⁇ -hydroxylysine, and arginine.
- examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid.
- mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid
- organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluen
- the 3-substituted-4-pyrimidone derivatives represented by the aforementioned formula (I) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the pyrimidone derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers of pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention
- Particularly preferred compounds of the present invention represented by formula (I) include:
- Salts of the aforementioned preferred compound, and solvates or hydrates of the aforementioned compounds and salts thereof are also preferred.
- the 2-thiopyrimidone represented by the above formula (XI) is prepared easily by a modification of the method described in EP 354,179.
- the reaction is carried out in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium t-butoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200°C under nitrogen or argon atmosphere or under ordinary air to afford the desired compound (XI).
- a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium t-butoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diaza
- a solvent for the reactions examples include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like.
- alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert
- the 2-thiopyrimidone derivative (XI) is transformed into the 2-chloropyrimidone (XII) by a chlorinating agent.
- the reaction time and temperature depend on the chlorinating agent used. Examples of a chlorinating agent for the reactions include, for example, thionyl chloride, thionyl chloride and dimethylformamide, phosphorus oxychloride, phosphorus oxychloride and dimethylformamide, oxalyl chloride, phosphorous oxychloride and dimethylformamide, and phosphorus pentachloride.
- the amine represented by the above formula (XIII) or salts thereof is may be prepared by a modification of the method described in the literature (Tetrahedron Lett., 30, 5285 (1989), Synthesis, 122 (1990)).
- the chloride derivative (XII) is allowed to react with the amine (XIII) or salts thereof in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200°C under nitrogen or argon atmosphere or under ordinary air to afford the desired compound (I).
- a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200
- a solvent for the reactions examples include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like.
- alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert
- the chloride derivative (XII) is allowed to react with the amine (TVX) or salts thereof in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200°C under nitrogen or argon atmosphere or under ordinary air to afford the desired compound ( I ).
- a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to
- a solvent for the reactions examples include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like.
- alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert
- the amine represented by the above formula (VX) may be prepared by a modification of the method described in the literature (J. Med. Chem., 13, 1 (1970), J. Med. Chem., 41, 591 (1998)) or according to well-known methods of one skilled in the art.
- the chloride derivative (XII) is allowed to react with the amine (VX) or salts thereof in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200O under nitrogen or argon atmosphere or under ordinary air to afford the desired compound (I).
- a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200O
- a solvent for the reactions examples include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like.
- alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert
- the chloride derivative (XII) is allowed to react with the amine (VIX) or salts thereof in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200°C under nitrogen or argon atmosphere or under ordinary air to afford the desired compound (I).
- a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and l,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0°C to 200
- a solvent for the reactions examples include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like.
- alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert
- the compounds of the present invention have inhibitory activity against TPKl, and they inhibit TPKl activity in neurodegenerative diseases such as Alzheimer disease, thereby suppress the neurotoxicity of A ⁇ and the formation of PHF and inhibit the nerve cell death. Accordingly, the compounds of the present invention are useful as an active ingredient of a medicament which radically enables preventive and/or therapeutic treatment of Alzheimer disease.
- the compounds of the present invention are also useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to solitary cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitis, postencephalitic parkinsonism, pugilistic encephalosis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma, non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and several virus-induced tumors.
- a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof.
- the substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives.
- a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives.
- two or more of the aforementioned substance may be used in combination.
- the above pharmaceutical composition may be supplemented with an active ingredient of other medicament for the treatment of Alzheimer disease and the above-mentioned diseases.
- a type of the pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration.
- the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like.
- Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracereb rally.
- Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition may be appropriately chosen by those skilled in the art.
- Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives.
- the pharmaceutical additives may be incorporated in a ratio ranging from 1% by weight to 90% by weight based on the weight of an active ingredient.
- excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like.
- a conventional inert diluent such as water or a vegetable oil may be used.
- the liquid composition may contain, in addition to the inert diluent, auxiliaries such as moistening agents, suspension aids, sweeteners, aromatics, colorants, and preservatives.
- the liquid composition may be filled in capsules made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g.
- injections, suppositories include water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like.
- base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol.
- Dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like.
- a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days.
- administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.
- Phosphorous oxychloride (26.11g, 170 mmol) was added to dimethylformamide(180 ml) and stirred 20 min.
- Example 7 Synthesis of l-(l-Methyl-6-oxo-4-pyridin-4-yl-l,6-dihydro-pyrimidine- 2-yl)-piperidine-3-carboxanilide (Compound No. C067 in Table-1)
- Grignard's reagent was prepared by reaction of magnesium(932 mg, 5.93mmol) with bromobenzene(144 mg,5.93 mmol) in diethyl ether(20 ml) at room temperature for 10 min. After cooling to 0°C, a solution of 2-cyano-4-benzyl- morpholineQ.OO g, 4.94 mmol) in diethyl ether(2.0 ml) was added and then tetrahydrofuran(6.0 ml) was added. The mixture was stirred at room temperature for 30 min. After decomposition with saturated aqueous sodium hydrogen carbonate, the mixture was filtered and concentrated under reduced pressure.
- Test Example Inhibitory activity of the medicament of the present invention against P-GS1 phosphorylation by bovine cerebral TPKl
- the phosphorylation was started by adding ATP, and the reaction was conducted at 25°C for 2 hours, and then stopped by adding 21% perchloric acid on ice cooling.
- the reaction mixture was centrifuged at 12,000 rpm for 5 minutes and adsorbed on P81 paper (Whatmann), and then the paper was washed four times with 75 mM phosphoric acid, three times with water and once with acetone.
- the paper was dried, and the residual radioactivity was measured using a liquid scintillation counter. The results are shown in the table below.
- the test compound markedly inhibited the P-GSl phosphorylation by TPKl.
- the medicaments of the present invention inhibit the TPKl activity, thereby suppress the A ⁇ neurotoxicity and the PHF formation, and that the medicaments of the present invention are effective for preventive and/or therapeutic treatment of Alzheimer disease and the above-mentioned diseases.
- the compounds of the present invention have TPKl inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal advance of TPKl such as neurodegenerative diseases (e.g. Alzheimer disease) and the above-mentioned diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200400453A EA007576B1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
IL16070002A IL160700A0 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
NZ531636A NZ531636A (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives as tau protein kinase 1 inhibitor |
BR0212892-6A BR0212892A (en) | 2001-09-21 | 2002-09-20 | 4-Pyrimidone-3-substituted derivatives |
CA2460121A CA2460121C (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
KR1020047004112A KR100881821B1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
JP2003540169A JP4347050B2 (en) | 2001-09-21 | 2002-09-20 | 3-Substituted-4-pyrimidone derivatives |
SI200230816T SI1427720T1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
MXPA04002662A MXPA04002662A (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives. |
HU0401900A HUP0401900A3 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates |
AU2002337499A AU2002337499B2 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
DK02772871T DK1427720T3 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone |
EP02772871A EP1427720B1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
DE60231414T DE60231414D1 (en) | 2001-09-21 | 2002-09-20 | 3-SUBSTITUTED 4-PYRIMIDONE DERIVATIVES |
US10/489,606 US7427615B2 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
IL160700A IL160700A (en) | 2001-09-21 | 2004-03-03 | 3-substituted-4-pyrimidone derivatives and medicaments comprising them for the treatment of neurodegenerative disease |
NO20041600A NO325781B1 (en) | 2001-09-21 | 2004-04-20 | 3-substituted 4-pyrimidone derivatives |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-331677 | 2001-09-21 | ||
JP2001331677 | 2001-09-21 | ||
JP2001-331674 | 2001-09-21 | ||
JP2001-331678 | 2001-09-21 | ||
JP2001331674 | 2001-09-21 | ||
JP2001-331675 | 2001-09-21 | ||
JP2001331678 | 2001-09-21 | ||
JP2001331675 | 2001-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003037888A1 true WO2003037888A1 (en) | 2003-05-08 |
Family
ID=27482651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/009685 WO2003037888A1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
Country Status (24)
Country | Link |
---|---|
US (1) | US7427615B2 (en) |
EP (1) | EP1427720B1 (en) |
JP (1) | JP4347050B2 (en) |
KR (1) | KR100881821B1 (en) |
CN (1) | CN100488958C (en) |
AT (1) | ATE424393T1 (en) |
AU (1) | AU2002337499B2 (en) |
BR (1) | BR0212892A (en) |
CA (1) | CA2460121C (en) |
CY (1) | CY1110317T1 (en) |
DE (1) | DE60231414D1 (en) |
DK (1) | DK1427720T3 (en) |
EA (1) | EA007576B1 (en) |
ES (1) | ES2323576T3 (en) |
HU (1) | HUP0401900A3 (en) |
IL (2) | IL160700A0 (en) |
MX (1) | MXPA04002662A (en) |
NO (1) | NO325781B1 (en) |
NZ (1) | NZ531636A (en) |
PL (1) | PL368671A1 (en) |
PT (1) | PT1427720E (en) |
SI (1) | SI1427720T1 (en) |
TW (1) | TWI265164B (en) |
WO (1) | WO2003037888A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004055007A1 (en) * | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
WO2004085408A1 (en) * | 2003-03-26 | 2004-10-07 | Mitsubishi Pharma Corporation | 2, 3, 6-trisubstituted-4-pyrimidone derivatives |
WO2005016911A1 (en) * | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
WO2006028290A1 (en) * | 2004-09-09 | 2006-03-16 | Mitsubishi Pharma Corporation | 2-morpholino-4-pyrimidone compound |
WO2006041404A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
WO2006041405A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
WO2006036015A3 (en) * | 2004-09-29 | 2006-06-01 | Mitsubishi Pharma Corp | 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors |
WO2006123257A2 (en) | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
US7256199B1 (en) | 1998-09-25 | 2007-08-14 | Mitsubishi Chemical Corporation | Pyrimidone derivatives |
WO2008023239A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
US7572793B2 (en) | 2001-09-21 | 2009-08-11 | Mitsubishi Tanabe Pharma Corporation | 3-Substituted-4-pyrimidone derivatives |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7781584B2 (en) | 2004-03-15 | 2010-08-24 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7834035B2 (en) | 2003-11-06 | 2010-11-16 | Addex Pharma Sa | Allosteric modulators of metabotropic glutamate receptors |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2011019089A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
WO2011019090A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2423207A2 (en) | 2006-03-15 | 2012-02-29 | Mitsubishi Tanabe Pharma Corporation | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8592417B2 (en) | 2006-12-26 | 2013-11-26 | Mitsubishi Tanabe Pharma Corporation | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US9108957B2 (en) | 2009-04-02 | 2015-08-18 | Mitsubishi Tanabe Pharma Corporation | 3-[1,4]oxazepane-4-pyrimidone derivatives |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
KR20100074182A (en) | 2007-09-14 | 2010-07-01 | 미쓰비시 타나베 파마 코퍼레이션 | 6-pyrimidinyl-pyrimid-2-one derivative |
US8288383B2 (en) * | 2007-09-14 | 2012-10-16 | Sanofi | 3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor |
US20130123281A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
SG11201702185UA (en) | 2014-09-29 | 2017-04-27 | Chemocentryx Inc | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
BR112018014222A2 (en) | 2016-01-14 | 2018-12-11 | Chemocentryx, Inc. | c3 glomerulopathy treatment method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
WO2000018758A1 (en) * | 1998-09-25 | 2000-04-06 | Mitsubishi Chemical Corporation | Pyrimidone derivatives |
EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4935631B1 (en) | 1970-12-28 | 1974-09-25 | ||
JPS559099B2 (en) | 1972-08-07 | 1980-03-07 | ||
JPS4935633A (en) | 1972-08-09 | 1974-04-02 | ||
JPS4935632A (en) | 1972-08-10 | 1974-04-02 | ||
JPS5124008B2 (en) | 1972-08-10 | 1976-07-21 | ||
JPS5271481A (en) | 1975-12-10 | 1977-06-14 | Yoshitomi Pharmaceut Ind Ltd | Synthesis of pyridylpyrimidines |
JPS52139085A (en) | 1976-05-13 | 1977-11-19 | Hokuriku Pharmaceutical | 22allylpiperazine derivative and method for its preparation |
US4507302A (en) * | 1979-03-19 | 1985-03-26 | The Upjohn Company | Method for treating arthritis with 6-aryl pyrimidine compounds |
US4619933A (en) * | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
EP0354179B1 (en) | 1988-07-29 | 1994-08-17 | Ciba-Geigy Ag | Thiouracils as stabilizers for polymers containing chlorine |
ES2302343T3 (en) | 1991-12-06 | 2008-07-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | USE OF PROTEIN KINASES FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE. |
DE4206145A1 (en) | 1992-02-28 | 1993-09-02 | Basf Ag | HERBICIDES N - ((PYRIMIDIN-2-YL) AMINOCARBONYL) BENZOLFULFONAMIDE |
JP3324611B2 (en) | 1992-07-03 | 2002-09-17 | 三菱化学株式会社 | Method for phosphorylating tau protein |
JPH06329551A (en) | 1993-03-22 | 1994-11-29 | Mitsubishi Kasei Corp | Preventing or therapeutic agent for alzheimer disease and method for screening thereof |
JPH07179442A (en) * | 1993-10-08 | 1995-07-18 | Sagami Chem Res Center | 4-iminooxazolidin-2-one derivative, its production and herbicide containing the same as active ingredient |
NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
AU733877C (en) | 1996-12-05 | 2003-05-08 | Amgen, Inc. | Substituted pyrimidine compounds and their use |
RU2277911C2 (en) * | 2000-02-25 | 2006-06-20 | Ф.Хоффманн-Ля Рош Аг | Modulators of adenosine receptors |
AU2001262150A1 (en) | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
EP1427709B1 (en) | 2001-09-21 | 2005-12-14 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
JP4616003B2 (en) | 2002-12-16 | 2011-01-19 | 田辺三菱製薬株式会社 | 3-substituted-4-pyrimidone derivatives |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
-
2002
- 2002-09-20 SI SI200230816T patent/SI1427720T1/en unknown
- 2002-09-20 WO PCT/JP2002/009685 patent/WO2003037888A1/en active IP Right Grant
- 2002-09-20 IL IL16070002A patent/IL160700A0/en unknown
- 2002-09-20 BR BR0212892-6A patent/BR0212892A/en not_active Application Discontinuation
- 2002-09-20 ES ES02772871T patent/ES2323576T3/en not_active Expired - Lifetime
- 2002-09-20 EA EA200400453A patent/EA007576B1/en not_active IP Right Cessation
- 2002-09-20 JP JP2003540169A patent/JP4347050B2/en not_active Expired - Fee Related
- 2002-09-20 CA CA2460121A patent/CA2460121C/en not_active Expired - Fee Related
- 2002-09-20 MX MXPA04002662A patent/MXPA04002662A/en active IP Right Grant
- 2002-09-20 CN CNB028184696A patent/CN100488958C/en not_active Expired - Fee Related
- 2002-09-20 AT AT02772871T patent/ATE424393T1/en active
- 2002-09-20 PT PT02772871T patent/PT1427720E/en unknown
- 2002-09-20 NZ NZ531636A patent/NZ531636A/en not_active IP Right Cessation
- 2002-09-20 DE DE60231414T patent/DE60231414D1/en not_active Expired - Lifetime
- 2002-09-20 AU AU2002337499A patent/AU2002337499B2/en not_active Ceased
- 2002-09-20 KR KR1020047004112A patent/KR100881821B1/en not_active IP Right Cessation
- 2002-09-20 TW TW091121655A patent/TWI265164B/en not_active IP Right Cessation
- 2002-09-20 PL PL02368671A patent/PL368671A1/en unknown
- 2002-09-20 US US10/489,606 patent/US7427615B2/en not_active Expired - Fee Related
- 2002-09-20 HU HU0401900A patent/HUP0401900A3/en unknown
- 2002-09-20 EP EP02772871A patent/EP1427720B1/en not_active Expired - Lifetime
- 2002-09-20 DK DK02772871T patent/DK1427720T3/en active
-
2004
- 2004-03-03 IL IL160700A patent/IL160700A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041600A patent/NO325781B1/en not_active IP Right Cessation
-
2009
- 2009-05-28 CY CY20091100562T patent/CY1110317T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
WO2000018758A1 (en) * | 1998-09-25 | 2000-04-06 | Mitsubishi Chemical Corporation | Pyrimidone derivatives |
EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 84, no. 7, 1976, Columbus, Ohio, US; abstract no. 44112b, page 502; XP002127060 * |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7256199B1 (en) | 1998-09-25 | 2007-08-14 | Mitsubishi Chemical Corporation | Pyrimidone derivatives |
US7572793B2 (en) | 2001-09-21 | 2009-08-11 | Mitsubishi Tanabe Pharma Corporation | 3-Substituted-4-pyrimidone derivatives |
US7683069B2 (en) | 2002-12-16 | 2010-03-23 | Mitsubishi Tanabe Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
WO2004055007A1 (en) * | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
EA009027B1 (en) * | 2002-12-16 | 2007-10-26 | Мицубиси Фарма Корпорейшн | 3-substituted-4-pirimidone derivatives |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AU2004223987B2 (en) * | 2003-03-26 | 2010-02-18 | Mitsubishi Tanabe Pharma Corporation | 2, 3, 6-trisubstituted-4-pyrimidone derivatives |
US7504411B2 (en) | 2003-03-26 | 2009-03-17 | Mitsubishi Tanabe Pharma Corporation | 2,3,6-Trisubstituted-4-pyrimidone derivatives |
EP2308854A1 (en) * | 2003-03-26 | 2011-04-13 | Sanofi-Aventis | 2,3,6-trisubstituted-4-pyrimidone derivatives |
JP2006521370A (en) * | 2003-03-26 | 2006-09-21 | 三菱ウェルファーマ株式会社 | 2,3,6-substituted-4-pyrimidone derivatives |
EA009620B1 (en) * | 2003-03-26 | 2008-02-28 | Мицубиси Фарма Корпорейшн | 2,3,6-trisubstituted-4-pyrimidone derivatives |
WO2004085408A1 (en) * | 2003-03-26 | 2004-10-07 | Mitsubishi Pharma Corporation | 2, 3, 6-trisubstituted-4-pyrimidone derivatives |
EP2305651A1 (en) * | 2003-03-26 | 2011-04-06 | Mitsubishi Tanabe Pharma Corporation | 2,3,6-trisubstituted-4-pyrimidone derivatives |
US7790736B2 (en) | 2003-08-13 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7723344B2 (en) | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2005016911A1 (en) * | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7834035B2 (en) | 2003-11-06 | 2010-11-16 | Addex Pharma Sa | Allosteric modulators of metabotropic glutamate receptors |
US8030331B2 (en) | 2003-11-06 | 2011-10-04 | Addex Pharma Sa | Allosteric modulators of metabotropic glutamate receptors |
US8163775B2 (en) | 2003-11-06 | 2012-04-24 | Addex Pharma Sa | Allosteric modulators of metabotropic glutamate receptors |
US8288539B2 (en) | 2004-03-15 | 2012-10-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7906523B2 (en) | 2004-03-15 | 2011-03-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8329900B2 (en) | 2004-03-15 | 2012-12-11 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8188275B2 (en) | 2004-03-15 | 2012-05-29 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8173663B2 (en) | 2004-03-15 | 2012-05-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7781584B2 (en) | 2004-03-15 | 2010-08-24 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7807689B2 (en) | 2004-03-15 | 2010-10-05 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2008512347A (en) * | 2004-09-09 | 2008-04-24 | 田辺三菱製薬株式会社 | 2-morpholino-4-pyrimidone compounds |
EP2266979A1 (en) * | 2004-09-09 | 2010-12-29 | Mitsubishi Tanabe Pharma Corporation | 2-morpholino-4-pyrimidone compounds |
WO2006028290A1 (en) * | 2004-09-09 | 2006-03-16 | Mitsubishi Pharma Corporation | 2-morpholino-4-pyrimidone compound |
EA013839B1 (en) * | 2004-09-09 | 2010-08-30 | Мицубиси Танабе Фарма Корпорейшн | 2-morpholino-4-pyrimidine compound |
US8106045B2 (en) | 2004-09-09 | 2012-01-31 | Mitsubishi Tanabe Pharma Corporation | 2-morpholino-4-pyrimidone compound |
AU2005280885B2 (en) * | 2004-09-09 | 2011-09-22 | Mitsubishi Tanabe Pharma Corporation | 2-morpholino-4-pyrimidone compound |
EP2258701A1 (en) * | 2004-09-09 | 2010-12-08 | Mitsubishi Tanabe Pharma Corporation | 2-morpholino-4-pyrimidone compound |
US8129377B2 (en) | 2004-09-29 | 2012-03-06 | Mitsubishi Tanabe Pharma Corporation | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
JP2008514587A (en) * | 2004-09-29 | 2008-05-08 | 田辺三菱製薬株式会社 | 6-pyridinyl-4-pyrimidone derivatives as tau protein kinase 1 inhibitors |
EP2266969A3 (en) * | 2004-09-29 | 2011-02-16 | Mitsubishi Tanabe Pharma Corporation | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors |
EP2261224A3 (en) * | 2004-09-29 | 2011-02-16 | Mitsubishi Tanabe Pharma Corporation | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors |
AU2005288045B2 (en) * | 2004-09-29 | 2011-08-18 | Mitsubishi Tanabe Pharma Corporation | 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors |
EA013004B1 (en) * | 2004-09-29 | 2010-02-26 | Мицубиси Танабе Фарма Корпорейшн | 6-(pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors |
WO2006036015A3 (en) * | 2004-09-29 | 2006-06-01 | Mitsubishi Pharma Corp | 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors |
JP2008516946A (en) * | 2004-10-15 | 2008-05-22 | アストラゼネカ・アクチエボラーグ | Substituted amino-pyrimidones and their use |
WO2006041404A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
WO2006041405A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
JP2008516945A (en) * | 2004-10-15 | 2008-05-22 | アストラゼネカ・アクチエボラーグ | Substituted amino compounds and their use |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006123257A3 (en) * | 2005-05-18 | 2007-05-03 | Addex Pharmaceuticals Sa | Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
EA014081B1 (en) * | 2005-05-18 | 2010-08-30 | Аддекс Фарма Са | Pyrrole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
WO2006123257A2 (en) | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP2423207A3 (en) * | 2006-03-15 | 2012-06-13 | Mitsubishi Tanabe Pharma Corporation | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors |
EP2423207A2 (en) | 2006-03-15 | 2012-02-29 | Mitsubishi Tanabe Pharma Corporation | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors |
US8569294B2 (en) | 2006-03-15 | 2013-10-29 | Mitsubishi Tanabe Pharma Corporation | 2-(cyclic amino)-pyrimidone derivatives |
US20100292205A1 (en) * | 2006-08-23 | 2010-11-18 | Pfizer Inc. | Pyrimidone Compounds As GSK-3 Inhibitors |
WO2008023239A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8592417B2 (en) | 2006-12-26 | 2013-11-26 | Mitsubishi Tanabe Pharma Corporation | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US9108957B2 (en) | 2009-04-02 | 2015-08-18 | Mitsubishi Tanabe Pharma Corporation | 3-[1,4]oxazepane-4-pyrimidone derivatives |
JP2013501708A (en) * | 2009-08-13 | 2013-01-17 | 田辺三菱製薬株式会社 | Pyrimidone derivatives as tau protein kinase 1 inhibitors |
WO2011019090A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
WO2011019089A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
US8940738B2 (en) | 2009-08-13 | 2015-01-27 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone compounds |
US9006232B2 (en) | 2009-08-13 | 2015-04-14 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives |
Also Published As
Publication number | Publication date |
---|---|
EP1427720A1 (en) | 2004-06-16 |
US7427615B2 (en) | 2008-09-23 |
KR20040054689A (en) | 2004-06-25 |
SI1427720T1 (en) | 2009-08-31 |
PT1427720E (en) | 2009-04-27 |
JP4347050B2 (en) | 2009-10-21 |
CY1110317T1 (en) | 2015-01-14 |
EP1427720B1 (en) | 2009-03-04 |
KR100881821B1 (en) | 2009-02-03 |
HUP0401900A2 (en) | 2004-12-28 |
DK1427720T3 (en) | 2009-05-04 |
CN100488958C (en) | 2009-05-20 |
EA007576B1 (en) | 2006-12-29 |
CN1556804A (en) | 2004-12-22 |
BR0212892A (en) | 2004-08-03 |
US20050090490A1 (en) | 2005-04-28 |
AU2002337499B2 (en) | 2007-08-23 |
ATE424393T1 (en) | 2009-03-15 |
PL368671A1 (en) | 2005-04-04 |
NO325781B1 (en) | 2008-07-14 |
ES2323576T3 (en) | 2009-07-21 |
CA2460121A1 (en) | 2003-05-08 |
MXPA04002662A (en) | 2004-11-22 |
CA2460121C (en) | 2010-11-02 |
HUP0401900A3 (en) | 2005-08-29 |
DE60231414D1 (en) | 2009-04-16 |
NO20041600L (en) | 2004-06-16 |
JP2005510506A (en) | 2005-04-21 |
IL160700A (en) | 2009-09-22 |
TWI265164B (en) | 2006-11-01 |
NZ531636A (en) | 2005-11-25 |
EA200400453A1 (en) | 2004-08-26 |
IL160700A0 (en) | 2004-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1427709B1 (en) | 3-substituted-4-pyrimidone derivatives | |
WO2003037888A1 (en) | 3-substituted-4-pyrimidone derivatives | |
AU2002337499A1 (en) | 3-substituted-4-pyrimidone derivatives | |
AU2002337498A1 (en) | 3-substituted-4-pyrimidone derivatives | |
KR100985419B1 (en) | 2,3,6-trisubstituted-4-pyrimidone derivatives | |
EP1789414A1 (en) | 2-morpholino-4-pyrimidone compound | |
EP2148866B1 (en) | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | |
EP1572681B1 (en) | 3-substituted-4-pyrimidone derivatives | |
WO2001070683A2 (en) | 3-substituted-4-pyrimidone derivatives | |
AU2003285777B2 (en) | 3-substituted-4-pyrimidone derivatives | |
MXPA05010323A (en) | 2, 3, 6-trisubstituted-4-pyrimidone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 160700 Country of ref document: IL Ref document number: 2002337499 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/01850 Country of ref document: ZA Ref document number: 200401850 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 531636 Country of ref document: NZ Ref document number: 2460121 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002772871 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003540169 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/002662 Country of ref document: MX Ref document number: 20028184696 Country of ref document: CN Ref document number: 1020047004112 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 819/CHENP/2004 Country of ref document: IN Ref document number: 200400453 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002772871 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10489606 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 531636 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 531636 Country of ref document: NZ |